FDA lifts holds on Epizyme, Sarepta programs

FDA lifted separate clinical holds on tazemetostat from Epizyme Inc. (NASDAQ:EPZM) and a gene therapy program targeting micro-dystrophin from Sarepta Therapeutics Inc. (NASDAQ:SRPT), the companies said Sept. 24.

Epizyme is reopening enrollment in all of its U.S. tazemetostat trials, in which new enrollment had been paused. FDA

Read the full 464 word article

User Sign In